Prelude Therapeutics Stock Volatility Indicators Average True Range
| PRLD Stock | USD 3.30 -0.07 -2.08% |
| Symbol |
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Prelude Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
Prelude Therapeutics Technical Analysis Modules
Most technical analysis of Prelude Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Prelude from various momentum indicators to cycle indicators. When you analyze Prelude charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Stock Overview, Methodology & Data Sources
Prelude Therapeutics is scheduled to announce its earnings this week.Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware. Prelude Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 112 people. This overview emphasizes how Prelude Therapeutics compares to peers on valuation quality and operating consistency. Current metrics include P/B of 3.55. Prelude Therapeutics has a market cap of 207.46 M, ROE of -99.45%.
Methodology
Unless otherwise specified, financial data for Prelude Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Prelude (USA Stocks:PRLD) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Prelude Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Prelude Therapeutics is covered by 3 analysts. 1 analyst has submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, Oppenheimer & Co., RBC Capital Markets, J.P. Morgan, Wells Fargo Securities, among others. Updates may occur throughout the day.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardLearn to be your own money manager
Tracking Prelude Therapeutics inside a portfolio is useful because individual winners can still weaken diversification or distort overall risk targets. A disciplined tracking process turns performance data into better decisions instead of more noise.
Did you try this?
Run Crypto Correlations Now
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
| All Next | Launch Module |
Prelude Therapeutics pair trading
Pair trading with Prelude Therapeutics can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. The key question is whether the second leg adds real hedge value instead of just creating a more complex version of the same risk.
Prelude Therapeutics Pair Trading
Prelude Therapeutics Pair Trading Analysis
The effectiveness of tax-loss harvesting on Prelude Therapeutics depends on finding a suitable replacement asset. Instruments with correlation above 0.9 to Prelude Therapeutics typically provide adequate market exposure during the required holding period.
Interpreting the correlation table for Prelude Therapeutics: readings above 0.8 indicate strongly correlated pairs with minimal diversification benefit, while readings between -0.2 and +0.2 around Prelude Therapeutics suggest near-independence and genuine portfolio diversification value.
Use Correlation analysis and pair trading evaluation for Prelude Therapeutics to review hedging context. The view can be extended across sectors or other related groups.More Resources for Prelude Stock Analysis
A comprehensive view of Prelude Therapeutics starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Prelude Therapeutics Stock. Key reports that frame Prelude Therapeutics Stock are listed below:Prelude Therapeutics has a market cap of 207.46 M, operating margin of -3.08%, ROE of -99.45%. Review Your Equity Center for broader portfolio context. This reflects a position in Prelude Therapeutics in the portfolio view. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. Our How to Invest in Prelude Therapeutics guide provides practical guidance on trading Prelude Stock.Analysis related to Prelude Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Earnings Share -1.47 | Revenue Per Share | Quarterly Revenue Growth 0.41 | Return On Assets | Return On Equity |
Understanding Prelude Therapeutics includes distinguishing between market value and book value, where book value reflects Prelude's accounting equity. Prelude Therapeutics' market capitalization is 207.46 M. With a P/B ratio of 3.55, the market values Prelude Therapeutics well above its book equity. Enterprise value stands at 170.67 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
It is useful to distinguish Prelude Therapeutics' value from its trading price, which are computed with different methods. For Prelude Therapeutics, key inputs include a P/B ratio of 3.55, ROE of -99.45%, and revenue of 12.14 M. By contrast, market price reflects the level where buyers and sellers transact.